TalhaBadarMD

PubMed

• Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eig...
  Yasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, Rory M Shallis, Andrew H Matthews, Talha Badar, Emily M Geramita, Vamsi K Kota, Alok Swaroop, Peter Doukas, D...> ;American Journal of Hematology. 2024 Apr 1
• Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: resul...
  Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Patel, Jan P Bewersdorf, Adam S ...> ;Blood Cancer Journal. 2024 Feb 20
• 12 citations
  Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive...
  Naseema Gangat, Omer Karrar, Moazah Iftikhar, Kristen McCullough, Isla M Johnson, Maymona Abdelmagid, Mostafa Abdallah, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begn...> ;American Journal of Hematology. 2024 Feb 1
• Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms.
  Anmol Baranwal, Mark Gurney, Rami Basmaci, Bahga Katamesh, Rong He, David S Viswanatha, Patricia Greipp, James Foran, Talha Badar, Hemant Murthy, Cecilia Arana Yi, Jea...> ;Haematologica. 2024 Feb 1
• VEXAS syndrome in a patient with DDX41 germline predisposition syndrome.
  Lasho, T., Finke, C., Kusne, Y., Patnaik, M., Badar, T.> ;Leukemia Research. 2024 Jan 1
• 1 citations
  TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
  Ayalew Tefferi, Farah Fleti, Onyee Chan, Najla H Al Ali, Aref Al-Kali, Kebede H Begna, James M Foran, Talha Badar, Nandita Khera, Mithun Shah, Devendra Hiwase, Eric Pa...> ;British Journal of Haematology. 2024 Apr 1
• The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
  Mark Gurney, Ismahene Chekkaf, Anmol Baranwal, Rami Basmaci, Bahga Katamesh, Patricia Greipp, James M Foran, Talha Badar, Abhishek A Mangaonkar, Kebede H Begna, Naseem...> ;British Journal of Haematology. 2023 Jul 1
• 3 citations
  Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome.
  Aref Al-Kali, Ahmad Nanaa, David Viswanatha, Rong He, Phuong Nguyen, Dragan Jevremovic, James M Foran, Cecelia Arana Yi, Patricia T Greipp, Naseema Gangat, Mrinal Patn...> ;Blood Cancer Journal. 2023 Apr 10
• Autoimmune manifestations in STAG2-mutated myeloid neoplasms.
  Katamesh, B., Nanaa, A., He, R., Viswanatha, D., Nguyen, P., Greipp, P., Foran, J., Begna, K., Gangat, N., Patnaik, M., Tefferi, A., Litzow, M., Mangaonkar, A., Shah, ...> ;Annals of Hematology. 2022 Dec 1
• 2 citations
  Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia.
  Sameem M Abedin, Talha Badar, Katelyn Gauger, Laura C Michaelis, Lyndsey Runaas, Karen-Sue Carlson, Gs Guru Murthy, Ehab Atallah> ;Leukemia Research. 2022 Dec 1
• Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms.
  Bahga Katamesh, Ahmad Nanaa, Rong He, David Viswanatha, Phuong Nguyen, Patricia Greipp, James Foran, Kebede Begna, Naseema Gangat, Mrinal Patnaik, Ayalew Tefferi, Mark...> ;Annals of Hematology. 2023 Jan 1
• 4 citations
  Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.
  Michael Boyiadzis, Mei-Jie Zhang, Karen Chen, Hisham Abdel-Azim, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Talha Badar, Sherif M Badawy, Minoo Battiwalla, Ne...> ;Leukemia. 2023 May 1
• 5 citations
  Limited activity of luspatercept in myelofibrosis and myeloid neoplasms other than myelodysplastic syndromes with ring sideroblasts.
  Naseema Gangat, Deandra Chetram, Kristen McCullough, Aref Al-Kali, Kebede Begna, William Hogan, Mark Litzow, James Foran, Talha Badar, Jeanne Palmer, Mrinal Patnaik, A...> ;American Journal of Hematology. 2022 Dec 1
• 2 citations
  Comparison between GATA2 and DDX41-mutated myeloid neoplasms.
  Nanaa, A., He, R., Viswanatha, D., Nguyen, P., Jevremovic, D., Foran, J., Yi, C., Greipp, P., Gangat, N., Patnaik, M., Tefferi, A., Litzow, M., Mangaonkar, A., Shah, M...> ;Leukemia Research. 2022 Oct 1
• 6 citations
  Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia.
  Anmol Baranwal, Ahmad Nanaa, David Viswanatha, Rong He, James Foran, Talha Badar, William J Hogan, Mark R Litzow, Mithun Vinod Shah, Mrinal M Patnaik, Aref Al-Kali, Ha...> ;Bone Marrow Transplantation. 2022 Nov 1
• 8 citations
  Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms.
  Talha Badar, Timothy Chlon> ;Current Hematologic Malignancy Reports. 2022 Oct 1
• 25 citations
  Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.
  Talha Badar, Ehab Atallah, Rory M Shallis, Aaron D Goldberg, Anand Patel, Yasmin Abaza, Jan P Bewersdorf, Antoine N Saliba, Guilherme Sacchi De Camargo Correia, Guru M...> ;American Journal of Hematology. 2022 Jul 1
• 2 citations
  Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs.
  Ahmad Ghorab, Aref Al-Kali, Michelle Elliot, Naseema Gangat, Hasan Alkhateeb, Mithun Shah, Yuanhang Liu, Cecilia Arana Yi, Hemant Murthy, Mohamed Kharfan-Dabaja, Ayale...> ;Blood Cancer Journal. 2022 Jun 24
• 11 citations
  Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.
  Gangat, N., McCullough, K., Johnson, I., Al-Kali, A., Begna, K., Patnaik, M., Litzow, M., Hogan, W., Shah, M., Alkhateeb, H., Mangaonkar, A., Foran, J., Badar, T., Pal...> ;American Journal of Hematology. 2022 Jun 1
• 13 citations
  Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts.
  Faiqa Farrukh, Deandra Chetram, Aref Al-Kali, James Foran, Mrinal Patnaik, Talha Badar, Kebede Begna, Christopher Hook, William Hogan, Kristen B McCullough, Abhishek M...> ;American Journal of Hematology. 2022 Jun 1
• 3 citations
  Prospect of CAR T-cell therapy in acute myeloid leukemia.
  Talha Badar, Alak Manna, Martha E Gadd, Mohamed A Kharfan-Dabaja, Hong Qin> ;Expert Opinion on Investigational Drugs. 2022 Feb 1
• 1 citations
  Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes.
  Yenny Moreno Vanegas, Talha Badar> ;Cancer Management and Research. 2022 Jan 1
• 2 citations
  Bladder Myeloid Sarcoma withmutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen.
  Nikeeta Mandhan, Farah Yassine, Ke Li, Talha Badar> ;Leukemia Research Reports. 2022 Jan 1
• 23 citations
  Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms.
  Hassan B. Alkhateeb, Ahmad Nanaa, David S. Viswanatha, James M. Foran, Talha Badar, Lisa Sproat, Rong He, Phuong L. Nguyen, Dragan Jevremovic, Mohamad E. Salama, Patri...> ;Blood Advances. 2021 Oct 13
• 22 citations
  Early Relapse Identifies MCL patients with Inferior Survival after Intensive or Less Intensive Frontline Therapy.
  David A. Bond, Jeffrey M. Switchenko, Diego Villa, Kami J. Maddocks, Michael C. Churnetski, Alina S. Gerrie, Subir Goyal, Krithika Shanmugasundaram, Oscar Calzada, Bha...> ;Blood Advances. 2021 Sep 13
• Join now to see all